0001415889-24-009364.txt : 20240328 0001415889-24-009364.hdr.sgml : 20240328 20240328180013 ACCESSION NUMBER: 0001415889-24-009364 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240327 FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dake Benjamin T CENTRAL INDEX KEY: 0001869248 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 24800965 MAIL ADDRESS: STREET 1: C/O AEROVATE THERAPEUTICS, INC. STREET 2: 200 BERKELEY STREET, FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-03282024_060301.xml X0508 4 2024-03-27 0001798749 Aerovate Therapeutics, Inc. AVTE 0001869248 Dake Benjamin T C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false SEE REMARKS 1 Common Stock 2024-03-27 4 M 0 11068 10.61 A 12359 D Common Stock 2024-03-27 4 S 0 11068 27.9652 D 1291 D Stock Option (Right to Buy) 10.61 2024-03-27 4 M 0 11068 0 D 2031-12-13 Common Stock 11068 29000 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.95 to $28.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments. Officer Title: President, Chief Operating Officer and Secretary /s/ George A. Eldridge, Attorney-in-Fact 2024-03-28